


renibus therapeutics

PREVENT. PROTECT. IMPROVE.

We are Dedicated to Transforming the Cardio,
Renal and Metabolic Diseases Treatment Paradigm



About Us

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporphin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations.

Veverimer (Alezuris™) is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in a Phase 2 trial.

RBT-3 (iron sucrose), one component of RBT-1, is a novel, low molecular weight iron nanoparticle that has the potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. RBT-3 has also demonstrated the potential to mitigate cisplatin induced nephrotoxicity in preclinical models. We are currently exploring opportunities to further the clinical development of RBT-3 in these potential indications.


RBT-9 (stannic protoporphin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated that RBT-9 has the potential to significantly improve clinical outcomes. Additional work is underway to help inform the future clinical development strategy.

RBT-2 ((tetrahydrocurcumin) is an oral antioxidant & antifibrotic drug that is in IND enabling studies targeting delaying CKD progression.

Quick Facts:

Founded in 2016 and
Headquartered in Southlake, TX

Robust pipeline of programs to prevent disease progression,
improve outcomes and protect against organ damage in cardio,
renal and metabolic diseases.



Leadership Team

Frank Stonebanks, MBA, *Co-Chief Executive Officer*

D. Jeff Keyser, RPh, JD, PhD, *Co-Chief Executive Officer*

Bhupinder Singh, MD, *Chief Medical Officer*

Jamie A. Donadio, *Chief Financial Officer*

Asha Ramdas, *SVP, Program Management, Technical Operations
& Manufacturing*

Board of Directors

Henrik Rasmussen, MD, PhD, *Chairman*

Frank Stonebanks, MBA, *Co-CEO & Director*

D. Jeff Keyser, RPh, JD, PhD, *Co-CEO, Secretary & Director*

Bhupinder Singh, MD, *Director*

Carlos Guillem, MBA, PhD, *Director*

We have developed a robust portfolio of products that act by activating multiple cytoprotective pathways.

Program	Indication/Condition	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights
RBT-1 Stannic protoporphin/iron sucrose	Reducing the risk of post op complications in cardiothoracic surgery					renibus therapeutics
Veverimer (Alezuris™)	Undisclosed					renibus therapeutics
RBT-3 Iron sucrose	Restoring iron levels and improving perioperative blood product utilization in cardiac surgery and/or the ER Cisplatin induced nephrotoxicity					renibus therapeutics
RBT-9 Stannic protoporphin	TBD					renibus therapeutics
RBT-2 Antioxidant and anti-fibrotic	Slows progression of CKD					renibus therapeutics

Our patients are the core of what we do.

We'd like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.



RBT-1 Pivotal
Phase 3 Study
Now Enrolling



Learn more at
renibus.com/patients



To learn more about Renibus visit renibus.com or scan the QR code to the right.

